Non-Small Cell Lung Cancer Clinical Trial Janssen

If you have EGFR-Positive
Non-Small-Cell Lung Cancer (NSCLC)

Your Journey May Include
a Different Path

EGFR-Positive Non-Small-Cell Lung Cancer
Clinical Research Studies

Non-Small-Cell Lung Cancer

Lung cancer is the second most common cancer in both men and women (after skin cancer).1

  • NSCLC is the most common form of lung cancer, accounting for more than 8 out of 10 cases2
  • Roughly 1 out of 3 people with NSCLC test positive for a change (or mutation) to the gene that produces epidermal growth factor receptor (EGFR), a protein that can cause cancer cells to grow and multiply when it is not working properly3

Janssen is currently conducting studies on investigational medicines for the potential treatment of NSCLC with EGFR mutations.

If you have EGFR-positive NSCLC, you may be able to take part in one of these Janssen studies.

See If You Are Eligible
Clinical Research Opportunities

New discoveries are being made every day in the treatment of cancer and the development of investigational medicines that aim to target mutations.

Janssen is currently conducting clinical research studies for patients with EGFR-positive NSCLC.

Learn More about Janssen’s Current Studies

This website includes information about clinical research studies in the United States. To see a list of participating countries please visit this page.

If you have EGFR-positive, non-small-cell lung cancer, your journey may include a different path.

Consider enrolling in a Janssen research study today.

See If You Are Eligible
Gene Mutations & NSCLC

Until recently, most non-small-cell lung cancers (NSCLC) were treated similarly, with therapies that destroy dividing cells (both cancer and healthy cells alike). Today, clinical research studies are evaluating the safety and efficacy of investigational medicines (with the goal of targeting certain mutations) to potentially treat NSCLC.

NSCLC happens when changes (or “mutations”) in your genes cause your lung cells to grow uncontrollably and cluster together to form tumours that lead to lung cancer.

EGFR-positive NSCLC is NSCLC that tests positive for a mutation of the EGFR gene and protein. EGFR is involved in cell growth and cell survival. When it mutates, it can cause cancer cells to grow and spread in the body. There are both rare and common EGFR mutations:

  • An example of a rare EGFR mutation is the Exon 20 insertion, which accounts for a small proportion of the NSCLC population.4
  • More common EGFR mutations (85%-90%) are Exon 19 deletion and Exon 21 L858R substitution.4

Investigational medicines are being developed that aim to target these various EGFR mutations.

Consider enrolling in a research study evaluating investigational medicines for NSCLC today.

See If You Are Eligible
How do I know if I have EGFR-Positive NSCLC?
Biomarker Testing

After you are diagnosed with NSCLC, you may need to get a biomarker test (sometimes called a “gene test” or “molecular test”) to see if you have a mutation that can be targeted.

It’s important to speak with your doctor about performing biomarker testing and reviewing the results so that you can better understand your potential options. Your results may also provide an opportunity for you to participate in clinical research.

Visit this page to learn more about Biomarker Testing.


If you do not know if your NSCLC is EGFR-positive, consult with your doctor to see if you should get tested.

This discussion guide contains information on biomarker testing that you can use when you speak to your doctor.

Download Discussion Guide
If you have EGFR-Positive Non-Small-Cell Lung Cancer, your journey may include a different path. 

The more we learn, the farther we can go.